StockDriftsStockDriftsTop 7 Enavate Sciences Gp LLC Holdings
| Stock | Company | % Port. | Shares | Value | Activity | Ownership | Avg. Cost | Date |
|---|---|---|---|---|---|---|---|---|
| SION | SIONNA THERAPEUTICS INC | 31.56% | 2.48M | $109.0M | +0.00%(+0) | $10.46(-38.24%) | 2026-06-30 | |
| ZBIO | ZENAS BIOPHARMA INC | 28.8% | 3.92M | $99.5M | +0.00%(+0) | $13.23(+123.10%) | 2026-06-30 | |
| IMNM | IMMUNOME INC | 22.17% | 3.61M | $76.6M | +0.00%(+0) | $11.55(+135.45%) | 2026-06-30 | |
| BBOT | BRIDGEBIO ONCOLOGY THERAPEUT | 5.8% | 2.63M | $20.0M | +0.00%(+0) | $11.10(-18.38%) | 2026-06-30 | |
| CMPX | COMPASS THERAPEUTICS INC | 4.94% | 7.79M | $17.1M | +0.00%(+0) | $1.65(+36.78%) | 2026-06-30 | |
| UPB | UPSTREAM BIO INC | 4.93% | 2.46M | $17.0M | +0.00%(+0) | $16.44(-57.00%) | 2026-06-30 | |
| CAMP | CAMP4 THERAPEUTICS CORP | 1.8% | 1.43M | $6.2M | -34.93%(-765.38K) | $5.22(+4.21%) | 2026-06-30 |
| Performance Metric | 3-Year Annualized | 3-Year Cumulative | 5-Year Annualized | 5-Year Cumulative | Since First Filing (6 quarters) |
|---|---|---|---|---|---|
| Top 20 Holdings Weighted | — | — | — | — | +81.40% |
| Top 20 Holdings Unweighted | — | — | — | — | +96.19% |
Enavate Sciences Gp LLC reports $345.38M in US-listed equity holdings across 7 positions in its most recent 13F filing. Its largest disclosed positions are SION (31.6%), ZBIO (28.8%) and IMNM (22.2%). The top 20 holdings account for 100% of reported assets. Its disclosed equity book has returned +81.40% cumulatively over 6 quarters. Figures reflect the Q2 2026 filing.
Portfolio changes
Every reported change this quarter, grouped by direction. The signal is in the rotation, not any single trade.
Sign up free to track Enavate Sciences Gp LLC, compare funds side by side, and get alerts the moment positions change.
Holdings on this page are parsed from Enavate Sciences Gp LLC’s Form 13F filings with the U.S. Securities and Exchange Commission (CIK 1953107). View Enavate Sciences Gp LLC’s 13F filings on SEC